Chuangmei Pharmaceutical (02289) issued an announcement. The Group expects the year ended December 31, 2023 (reporting period...
Zhitong Finance App News, Chuangmei Pharmaceutical (02289) announced that the Group expects net profit attributable to shareholders of the parent company for the year ended December 31, 2023 (reporting period) to decrease by about 45% compared to the year ended December 31, 2022 (same period last year).
According to the announcement, the sharp decline in expectations is mainly due to the company's one-time after-tax revenue of about RMB 49 million from cash compensation from land collection and storage during the same period last year, and there was no such revenue during the reporting period. On the other hand, the Group's net profit after deducting non-recurring profit and loss during the reporting period is expected to increase by about 22% compared to the same period last year. This expected increase is mainly due to the company's adherence to the “non-tendered market” business position and adhering to the “deepening Guangdong market” market strategy, winning recognition and support from more brand manufacturers, and obtaining distribution rights and project cooperation opportunities for more advantageous products. On the other hand, the company's product satisfaction rate and supply chain service advantages were recognized by customers, brand awareness was further enhanced, and the main business showed good performance.